长春瑞滨联合顺铂治疗对蒽环类及紫杉类耐药晚期乳腺癌的疗效观察

摘要

Objective:To investigate the clinical efficacy of Changchun vinorelbine combined with cisplatin to anthracycline and taxane resistant metastatic breast cancer.Methods:38 cases of anthracycline and taxane resistant advanced breast cancer patients were selected.They were given the Changchun vinorelbine plus cisplatin treatment.We observed its clinical effect.Results:After treatment,2 cases were CR;12 cases were PR;the efficiency rate was 36.8%.The average survival time was(13.6±3.5) months.The progression time was(5.3±1.4) months.The survival rate after the 12 months treatment was 68.4%.The main adverse reactions were gastrointestinal reaction and bone marrow suppression.Conclusion:The recent curative effect of Changchun vinorelbine plus cisplatin in the treatment of anthracycline and taxane resistant metastatic breast cancer is satisfaction,and the adverse reactions can be tolerated.%目的：探讨长春瑞滨联合顺铂对蒽环类及紫杉类耐药晚期乳腺癌的临床疗效。方法：收治对蒽环类及紫杉类耐药晚期乳腺癌患者38例，均给予其长春瑞滨联合顺铂治疗，观察其临床疗效。结果：本组38例患者经治疗后， CR 2例，PR 12例，有效率36.8%；平均生存时间(13.6±3.5)个月；疾病进展时间(5.3±1.4)个月；治疗12个月后的生存率68.4%；不良反应主要为胃肠道反应及骨髓抑制。结论：长春瑞滨联合顺铂治疗对蒽环类及紫杉类耐药晚期乳腺癌近期疗效满意，不良反应可耐受。